In a comparative effectiveness clinical trial of early RA patients, routinely checked lipids, such as total cholesterol (TC), LDL-C, and high-density lipoprotein cholesterol (HDL-C) were observed to increase across all treatment arms, including methotrexate (MTX) in combination with tumor necrosis factor inhibitor (TNFi), triple therapy (MTX, sulfasalazine (SSZ), and hydroxychloroquine (HCQ)), as well as MTX monotherapy [2]. The gene discussed is TNF; the disease is rheumatoid arthritis.